Such an assertion is supported by the recent findings that variation in FGFR2 and PRDM1 influences the risk of second cancer in HL survivors.35,36 For lung cancer, we were able to demonstrate a greater than additive interaction between family history of lung cancer and HL treatment, which may be the consequence of additional shared nongenetic risk factors, most probably a propensity to smoke. The gene discussed is PRDM1; the disease is lung carcinoma.